-
AstraZeneca and MSD’s Lynparza Gets Green Light for Prostate Cancer Treatment in Japan
•
Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted AstraZeneca (AZ; NASDAQ: AZN) and Merck, Sharp & Dohme (MSD; NYSE: MRK) a regulatory nod for the use of Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone as a treatment for BRCA-mutated (BRCAm) castration-resistant prostate cancer with distant…
-
AstraZeneca Restructures to Capture Opportunities in Guangdong-Hong Kong-Macao Greater Bay Area
•
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) is taking strategic steps to capitalize on the opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) by adjusting its team structure and changing personnel. New Divisional Leadership for GBA ExpansionAstraZeneca will split its respiratory, digestive, and autoimmune business unit into two distinct…
-
Cordavis Launches First Biosimilar: Novartis’ Hyrimoz to Compete with Humira
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz’s biosimilar product, Hyrimoz (adalimumab), which references AbbVie’s (NYSE: ABBV) Humira, has been announced as the first product offered by Cordavis, a newly launched biosimilars-focused subsidiary of US health solutions company CVS Health (NYSE: CVS). The biologic is planned for launch during Q1…
-
Microport EP Medtech’s Cryoablation Catheter and Equipment Approved as Innovative Devices in China
•
Shanghai Microport EP Medtech Co., Ltd has announced that its balloon type cryoablation catheter and cryoablation equipment have been approved for marketing as innovative devices in China. This marks a significant advancement in the treatment of drug-resistant, recurrent, and symptomatic paroxysmal atrial fibrillation, with the devices being the first of…
-
CSPC Pharmaceutical’s Generic Entresto Approved in China for Heart Failure Treatment
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Swiss giant Novartis’s (NYSE: NVS) heart failure therapy, Entresto (sacubitril, valsartan), has been approved for marketing in China. This approval comes on the same day as its compatriot firm Nanjing F&S Pharmatech Co., Ltd secured the…
-
Akeso Biopharma’s Ivonescimab Heads for Priority Review for NSCLC Treatment
•
China-based Akeso Biopharma (HKG: 9926) has announced that its bispecific antibody (BsAb) ivonescimab (AK112), targeting programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), is on course for priority review for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations that progress after treatment…
-
3SBio Inc. Reports H1 2023 Revenue Growth and Expansion in Digital Marketing
•
China-based 3SBio Inc. (HKG: 1530) has released its financial report for the first half of 2023, recording revenues of RMB 3.784 billion (USD 521 million), marking a 22.3% year-on-year (YOY) increase. Net profits reached RMB 1.191 billion, up 20.1% YOY. Product Sales and Market Share HighlightsTPIAO (recombinant human thrombopoietin [rhTPO]),…
-
GSK’s Shingrix Proves 100% Efficacy in Phase IV Trial for Chinese Patients
•
UK-based pharmaceutical giant GSK plc (NYSE: GSK) has released efficacy data for its shingles vaccine, Shingrix (recombinant zoster vaccine; RZV), in a Chinese patient population. The Phase IV post-marketing ZOSTER-076 trial, conducted in China, involved nearly 6,000 participants aged 50 and over. The trial reported no cases of shingles in…
